Anti–Heat Shock Protein 27 Antibody Levels and Diabetes Complications in the EURODIAB Study
- Davina Burt, PHD1,
- Graziella Bruno, MD1,
- Nish Chaturvedi, MRCP2,
- Casper Schalkwijk, PHD3,
- Coen D. Stehouwer, PHD3,
- Daniel R. Witte, PHD4,
- John H. Fuller, FRCP5,
- Silvia Pinach, MSC1,
- Paolo Cavallo Perin, MD1 and
- Gabriella Gruden, PHD1
- 1Department of Internal Medicine, University of Turin, Turin, Italy;
- 2National Heart and Lung Institute, Imperial College, London, U.K.;
- 3Department of Internal Medicine, Maastrict University Medical Centre, Maastricht, the Netherlands;
- 4Epidemiology Research Group, Steno Diabetes Center, Gentofte, Denmark;
- 5Department of Epidemiology and Public Health, Royal Free and University College London, Medical School, London, U.K.
- Corresponding author: Davina Burt, davina.burt{at}unito.it.
Abstract
OBJECTIVE To assess whether serum anti–heat shock protein 27 (HSP27) antibody levels are associated with micro- and macrovascular complications of type 1 diabetes.
RESEARCH DESIGN AND METHODS Anti-HSP27 IgG antibody levels were measured in 531 type 1 diabetic subjects recruited as part of the cross-sectional analysis of the EURODIAB Prospective Complications Study. Case subjects (n = 363) were defined as individuals with one or more diabetes complications and control subjects (n = 168) as individuals with no evidence of any diabetes complication.
RESULTS Anti-HSP27 levels were comparable in case and control subjects (19.6 arbitrary units/ml [11.3–32.7] vs. 20.4 arbitrary units/ml [11.7–35.3], geometric mean [interquartile range]), and there was no correlation between HSP27 and anti-HSP27 levels (r = 0.01, P = 0.81). In logistic regression analysis, anti-HSP27 was not associated with the presence of complications, even after adjustment for main risk factors.
CONCLUSIONS Anti-HSP27 antibody levels are not a marker of vascular complications in type 1 diabetes.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Received December 19, 2008.
- Accepted April 2, 2009.
-
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
- © 2009 by the American Diabetes Association.
